Morgan Stanley Immix Biopharma, Inc. Call Options Transaction History
Morgan Stanley
- $1.49 Trillion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMMX
# of Institutions
27Shares Held
2.67MCall Options Held
0Put Options Held
0-
Bleichroeder LP New York, NY850KShares$2.7 Million0.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA699KShares$2.22 Million0.0% of portfolio
-
Lynwood Capital Management Inc.405KShares$1.29 Million11.13% of portfolio
-
Geode Capital Management, LLC Boston, MA161KShares$512,3450.0% of portfolio
-
Northern Trust Corp Chicago, IL93.9KShares$298,5630.0% of portfolio
About Immix Biopharma, Inc.
- Ticker IMMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 13,910,100
- Market Cap $44.2M
- Description
- Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specif...